Video

Samsung Biologics Capacity Update October 2024: Large Molecule Drug Substance

Source: Samsung Biologics

Samsung Biologics is positioned as a powerful growth engine in biomanufacturing. Since our founding in 2011, we have delivered quality, speed, and agility to support our partners, establishing ourselves as the world’s largest CDMO with over 784kL of production capacity, soon to be expanded with Plant 5 coming online in Q3 2025.

Our commitment to innovation in large molecule manufacturing continues with planned expansions at Biocampus II, including Plants 6, 7, and 8, along with new facilities for ADC production, N-Perfusion (launching in May 2025), and Prefilled Syringe for fill-finish. These investments reflect our dedication to meeting the evolving needs of both current and future partners.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

Samsung Biologics